| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bayes Theorem | 54 | 2024 | 1021 | 5.500 |
Why?
|
| Breast Neoplasms | 158 | 2024 | 15694 | 4.550 |
Why?
|
| Research Design | 39 | 2022 | 1544 | 4.250 |
Why?
|
| Randomized Controlled Trials as Topic | 49 | 2020 | 2594 | 3.360 |
Why?
|
| Mammography | 25 | 2024 | 1010 | 3.320 |
Why?
|
| Clinical Trials as Topic | 49 | 2020 | 3719 | 3.160 |
Why?
|
| Neoadjuvant Therapy | 38 | 2024 | 4975 | 2.170 |
Why?
|
| Cytochrome P-450 CYP2D6 | 4 | 2014 | 43 | 1.900 |
Why?
|
| Models, Statistical | 23 | 2018 | 1171 | 1.650 |
Why?
|
| Data Interpretation, Statistical | 14 | 2015 | 482 | 1.550 |
Why?
|
| Early Detection of Cancer | 15 | 2024 | 1258 | 1.550 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 73 | 2024 | 15862 | 1.530 |
Why?
|
| Receptor, ErbB-2 | 35 | 2024 | 2518 | 1.450 |
Why?
|
| Mass Screening | 14 | 2018 | 1509 | 1.370 |
Why?
|
| Clinical Trials, Phase II as Topic | 8 | 2017 | 665 | 1.300 |
Why?
|
| Receptors, Estrogen | 27 | 2024 | 2086 | 1.230 |
Why?
|
| Biomarkers, Tumor | 33 | 2022 | 10331 | 1.040 |
Why?
|
| Chemotherapy, Adjuvant | 38 | 2021 | 3890 | 1.040 |
Why?
|
| Meta-Analysis as Topic | 6 | 2010 | 276 | 1.020 |
Why?
|
| Humans | 283 | 2024 | 261506 | 1.010 |
Why?
|
| Precision Medicine | 8 | 2018 | 1154 | 0.960 |
Why?
|
| DNA, Neoplasm | 4 | 2014 | 1910 | 0.950 |
Why?
|
| Drug Discovery | 6 | 2015 | 324 | 0.930 |
Why?
|
| Risk Assessment | 21 | 2020 | 6869 | 0.920 |
Why?
|
| Paclitaxel | 32 | 2024 | 1996 | 0.920 |
Why?
|
| Antineoplastic Agents | 24 | 2022 | 14289 | 0.860 |
Why?
|
| Biometry | 9 | 2018 | 241 | 0.860 |
Why?
|
| Neoplasms | 23 | 2018 | 15193 | 0.860 |
Why?
|
| Tamoxifen | 9 | 2014 | 876 | 0.850 |
Why?
|
| Disease-Free Survival | 40 | 2020 | 10001 | 0.840 |
Why?
|
| Comparative Effectiveness Research | 3 | 2012 | 126 | 0.830 |
Why?
|
| Random Allocation | 4 | 2016 | 703 | 0.830 |
Why?
|
| Clinical Trials, Phase I as Topic | 5 | 2014 | 604 | 0.810 |
Why?
|
| Female | 182 | 2024 | 141928 | 0.800 |
Why?
|
| Treatment Outcome | 70 | 2022 | 32848 | 0.750 |
Why?
|
| Survival Analysis | 41 | 2020 | 9180 | 0.740 |
Why?
|
| Genes, BRCA1 | 11 | 2007 | 387 | 0.730 |
Why?
|
| Antineoplastic Agents, Hormonal | 7 | 2018 | 840 | 0.720 |
Why?
|
| Biomedical Research | 6 | 2020 | 806 | 0.710 |
Why?
|
| Trastuzumab | 13 | 2024 | 696 | 0.620 |
Why?
|
| Aged | 96 | 2024 | 70117 | 0.620 |
Why?
|
| Middle Aged | 122 | 2024 | 86204 | 0.610 |
Why?
|
| Computer Simulation | 12 | 2022 | 1529 | 0.610 |
Why?
|
| Doxorubicin | 32 | 2020 | 3005 | 0.600 |
Why?
|
| Alzheimer Disease | 2 | 2023 | 855 | 0.600 |
Why?
|
| Neoplasm, Residual | 8 | 2022 | 1656 | 0.580 |
Why?
|
| United States Food and Drug Administration | 4 | 2020 | 332 | 0.580 |
Why?
|
| United States | 32 | 2024 | 15433 | 0.580 |
Why?
|
| Adult | 103 | 2024 | 77950 | 0.560 |
Why?
|
| Medical Oncology | 5 | 2015 | 1423 | 0.540 |
Why?
|
| Cyclophosphamide | 32 | 2020 | 3001 | 0.540 |
Why?
|
| Hospital Mortality | 1 | 2021 | 1274 | 0.530 |
Why?
|
| Clinical Trials, Phase III as Topic | 6 | 2017 | 447 | 0.530 |
Why?
|
| Drug Approval | 2 | 2015 | 178 | 0.520 |
Why?
|
| Sample Size | 8 | 2013 | 202 | 0.520 |
Why?
|
| Time Factors | 25 | 2021 | 12926 | 0.500 |
Why?
|
| Bias | 8 | 2022 | 205 | 0.490 |
Why?
|
| Minisatellite Repeats | 2 | 2004 | 51 | 0.480 |
Why?
|
| Neoplasm Recurrence, Local | 20 | 2020 | 10035 | 0.480 |
Why?
|
| Proportional Hazards Models | 20 | 2020 | 4988 | 0.480 |
Why?
|
| Zea mays | 2 | 2004 | 46 | 0.480 |
Why?
|
| Reproducibility of Results | 10 | 2015 | 6009 | 0.480 |
Why?
|
| Molecular Targeted Therapy | 5 | 2018 | 2330 | 0.480 |
Why?
|
| Models, Biological | 3 | 2021 | 3254 | 0.480 |
Why?
|
| Prognosis | 38 | 2022 | 21713 | 0.470 |
Why?
|
| Genes, BRCA2 | 6 | 2007 | 309 | 0.470 |
Why?
|
| Mastectomy, Segmental | 9 | 2016 | 1026 | 0.470 |
Why?
|
| Retinal Dehydrogenase | 1 | 2013 | 91 | 0.460 |
Why?
|
| Predictive Value of Tests | 22 | 2020 | 4892 | 0.460 |
Why?
|
| Mortality | 6 | 2024 | 343 | 0.450 |
Why?
|
| Kaplan-Meier Estimate | 16 | 2020 | 6207 | 0.450 |
Why?
|
| Hospitalization | 2 | 2021 | 2083 | 0.440 |
Why?
|
| Empirical Research | 1 | 2012 | 11 | 0.440 |
Why?
|
| Drugs, Investigational | 3 | 2010 | 135 | 0.440 |
Why?
|
| Probability | 12 | 2008 | 866 | 0.440 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 11 | 2022 | 6550 | 0.430 |
Why?
|
| Isoenzymes | 2 | 2013 | 614 | 0.420 |
Why?
|
| Endpoint Determination | 6 | 2020 | 176 | 0.410 |
Why?
|
| Age Factors | 17 | 2019 | 5377 | 0.410 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2014 | 105 | 0.400 |
Why?
|
| Risk Factors | 28 | 2020 | 17523 | 0.400 |
Why?
|
| Research Report | 1 | 2012 | 144 | 0.400 |
Why?
|
| Lymphatic Metastasis | 30 | 2017 | 4844 | 0.390 |
Why?
|
| Decision Support Techniques | 7 | 2004 | 622 | 0.380 |
Why?
|
| Decision Theory | 2 | 2007 | 9 | 0.380 |
Why?
|
| Pharmacy and Therapeutics Committee | 1 | 2010 | 2 | 0.380 |
Why?
|
| Esophagus | 1 | 2013 | 553 | 0.360 |
Why?
|
| Fluorouracil | 20 | 2019 | 1944 | 0.360 |
Why?
|
| Attitude to Health | 1 | 2013 | 465 | 0.360 |
Why?
|
| Aged, 80 and over | 33 | 2021 | 29902 | 0.350 |
Why?
|
| American Cancer Society | 1 | 2009 | 31 | 0.350 |
Why?
|
| Glioblastoma | 5 | 2022 | 1797 | 0.340 |
Why?
|
| Biomarkers | 7 | 2014 | 5047 | 0.330 |
Why?
|
| Doping in Sports | 1 | 2008 | 9 | 0.330 |
Why?
|
| Patient Selection | 5 | 2015 | 2055 | 0.330 |
Why?
|
| Neoplasm Staging | 30 | 2021 | 13658 | 0.330 |
Why?
|
| Vitamin E | 1 | 2009 | 136 | 0.330 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 361 | 0.320 |
Why?
|
| Immunity, Cellular | 1 | 2010 | 419 | 0.320 |
Why?
|
| Substance Abuse Detection | 1 | 2008 | 64 | 0.320 |
Why?
|
| Sports | 1 | 2008 | 80 | 0.310 |
Why?
|
| Insurance Coverage | 1 | 2010 | 256 | 0.310 |
Why?
|
| Internet | 4 | 2007 | 706 | 0.310 |
Why?
|
| Ovarian Neoplasms | 9 | 2007 | 4638 | 0.300 |
Why?
|
| Monte Carlo Method | 5 | 2011 | 671 | 0.300 |
Why?
|
| Genetic Testing | 5 | 2015 | 1589 | 0.300 |
Why?
|
| Drug Administration Schedule | 16 | 2015 | 3472 | 0.300 |
Why?
|
| False Positive Reactions | 6 | 2016 | 355 | 0.290 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2022 | 6915 | 0.290 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2019 | 1299 | 0.290 |
Why?
|
| Genes, erbB-2 | 4 | 2017 | 229 | 0.280 |
Why?
|
| Models, Theoretical | 5 | 2018 | 785 | 0.280 |
Why?
|
| Lod Score | 1 | 2005 | 157 | 0.270 |
Why?
|
| Age Distribution | 3 | 2018 | 698 | 0.270 |
Why?
|
| Antioxidants | 1 | 2009 | 507 | 0.270 |
Why?
|
| Medical Informatics | 2 | 2006 | 198 | 0.270 |
Why?
|
| Stroke | 3 | 2022 | 1144 | 0.260 |
Why?
|
| Antineoplastic Agents, Phytogenic | 8 | 2008 | 852 | 0.260 |
Why?
|
| Sensitivity and Specificity | 11 | 2014 | 4971 | 0.260 |
Why?
|
| Genes, Neoplasm | 2 | 2012 | 324 | 0.260 |
Why?
|
| Taxoids | 4 | 2020 | 967 | 0.260 |
Why?
|
| Hybridization, Genetic | 1 | 2004 | 17 | 0.260 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2017 | 1216 | 0.250 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2017 | 2796 | 0.250 |
Why?
|
| Markov Chains | 4 | 2011 | 175 | 0.250 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2021 | 3251 | 0.250 |
Why?
|
| Dietary Supplements | 1 | 2009 | 558 | 0.250 |
Why?
|
| Multicenter Studies as Topic | 9 | 2013 | 543 | 0.240 |
Why?
|
| Genetic Heterogeneity | 1 | 2005 | 318 | 0.240 |
Why?
|
| Spinal Diseases | 1 | 2005 | 125 | 0.240 |
Why?
|
| Esophageal Neoplasms | 2 | 2017 | 3168 | 0.240 |
Why?
|
| Lymphoma | 1 | 2012 | 1467 | 0.230 |
Why?
|
| Anticholesteremic Agents | 2 | 2004 | 256 | 0.230 |
Why?
|
| Decision Making, Computer-Assisted | 2 | 2005 | 32 | 0.230 |
Why?
|
| Anti-Arrhythmia Agents | 5 | 2010 | 226 | 0.230 |
Why?
|
| Mastectomy | 8 | 2017 | 1534 | 0.230 |
Why?
|
| Survival Rate | 17 | 2021 | 12221 | 0.230 |
Why?
|
| Spinal Fusion | 1 | 2005 | 149 | 0.230 |
Why?
|
| Fluorobenzenes | 1 | 2003 | 39 | 0.230 |
Why?
|
| Spine | 1 | 2005 | 293 | 0.230 |
Why?
|
| Quinolines | 2 | 2016 | 383 | 0.230 |
Why?
|
| Neuroprotective Agents | 1 | 2005 | 215 | 0.220 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2010 | 32 | 0.220 |
Why?
|
| Heptanoic Acids | 1 | 2003 | 96 | 0.220 |
Why?
|
| Adenocarcinoma | 5 | 2017 | 7789 | 0.220 |
Why?
|
| Colorectal Neoplasms | 2 | 2020 | 3578 | 0.220 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2017 | 1215 | 0.220 |
Why?
|
| Receptors, Progesterone | 9 | 2022 | 1392 | 0.210 |
Why?
|
| Colonic Neoplasms | 2 | 2014 | 1390 | 0.210 |
Why?
|
| Hematoma, Subdural, Acute | 1 | 2021 | 12 | 0.210 |
Why?
|
| Immunohistochemistry | 12 | 2013 | 7548 | 0.200 |
Why?
|
| Anthracyclines | 5 | 2016 | 331 | 0.200 |
Why?
|
| Capecitabine | 3 | 2019 | 388 | 0.200 |
Why?
|
| Hypothermia | 1 | 2021 | 59 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 17 | 2014 | 4938 | 0.200 |
Why?
|
| Bevacizumab | 3 | 2020 | 938 | 0.190 |
Why?
|
| Progestins | 2 | 2014 | 87 | 0.190 |
Why?
|
| Carcinoma, Lobular | 2 | 2017 | 611 | 0.190 |
Why?
|
| Hypercholesterolemia | 1 | 2003 | 259 | 0.190 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 32 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2015 | 3552 | 0.190 |
Why?
|
| Reperfusion Injury | 1 | 2021 | 145 | 0.190 |
Why?
|
| Software | 4 | 2011 | 1321 | 0.190 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2021 | 5319 | 0.190 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2010 | 598 | 0.190 |
Why?
|
| Antimalarials | 1 | 2020 | 55 | 0.190 |
Why?
|
| Immunotherapy | 3 | 2022 | 3341 | 0.180 |
Why?
|
| Odds Ratio | 6 | 2013 | 2316 | 0.180 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2021 | 209 | 0.180 |
Why?
|
| Kallikreins | 1 | 2020 | 84 | 0.180 |
Why?
|
| Brain Neoplasms | 4 | 2022 | 4849 | 0.180 |
Why?
|
| Hypothermia, Induced | 1 | 2021 | 170 | 0.180 |
Why?
|
| Male | 41 | 2021 | 123000 | 0.180 |
Why?
|
| Bridged-Ring Compounds | 1 | 2020 | 183 | 0.180 |
Why?
|
| Combined Modality Therapy | 17 | 2018 | 8865 | 0.180 |
Why?
|
| Cholesterol, LDL | 1 | 2003 | 565 | 0.170 |
Why?
|
| Carboplatin | 4 | 2016 | 823 | 0.170 |
Why?
|
| Hyperglycemia | 1 | 2022 | 333 | 0.170 |
Why?
|
| Radiosurgery | 2 | 2021 | 1330 | 0.170 |
Why?
|
| Neoplasm Metastasis | 15 | 2020 | 5112 | 0.170 |
Why?
|
| Regression Analysis | 7 | 2007 | 1546 | 0.170 |
Why?
|
| Pyrroles | 1 | 2003 | 576 | 0.170 |
Why?
|
| Disease Progression | 9 | 2020 | 6682 | 0.170 |
Why?
|
| SEER Program | 3 | 2007 | 1000 | 0.170 |
Why?
|
| Follow-Up Studies | 19 | 2021 | 14889 | 0.170 |
Why?
|
| Device Approval | 2 | 2011 | 21 | 0.170 |
Why?
|
| Congresses as Topic | 1 | 2020 | 298 | 0.170 |
Why?
|
| Incidence | 7 | 2016 | 5673 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2006 | 860 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2024 | 1555 | 0.160 |
Why?
|
| Multivariate Analysis | 12 | 2013 | 4298 | 0.160 |
Why?
|
| Hormone Replacement Therapy | 2 | 2013 | 205 | 0.160 |
Why?
|
| Heart Failure | 1 | 2012 | 2516 | 0.160 |
Why?
|
| Lung Neoplasms | 8 | 2021 | 11538 | 0.160 |
Why?
|
| Genetic Counseling | 3 | 2006 | 380 | 0.160 |
Why?
|
| Antibiotics, Antineoplastic | 5 | 2009 | 726 | 0.160 |
Why?
|
| Defibrillators, Implantable | 2 | 2011 | 221 | 0.160 |
Why?
|
| Young Adult | 11 | 2021 | 21445 | 0.150 |
Why?
|
| Attitude | 2 | 2016 | 159 | 0.150 |
Why?
|
| Genes, Tumor Suppressor | 2 | 1998 | 1064 | 0.150 |
Why?
|
| Medical History Taking | 2 | 1997 | 173 | 0.150 |
Why?
|
| Image Enhancement | 1 | 2021 | 561 | 0.150 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2016 | 2979 | 0.150 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2017 | 3 | 0.150 |
Why?
|
| Texas | 5 | 2021 | 6311 | 0.150 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2017 | 111 | 0.150 |
Why?
|
| Medical Overuse | 1 | 2017 | 45 | 0.150 |
Why?
|
| Early Termination of Clinical Trials | 2 | 2014 | 85 | 0.150 |
Why?
|
| Research Personnel | 2 | 2015 | 156 | 0.150 |
Why?
|
| Postmenopause | 2 | 2014 | 378 | 0.150 |
Why?
|
| Lymph Node Excision | 4 | 2021 | 1959 | 0.150 |
Why?
|
| Clinical Protocols | 2 | 2022 | 467 | 0.150 |
Why?
|
| Estrogens | 2 | 2014 | 751 | 0.150 |
Why?
|
| Lymph Nodes | 6 | 2017 | 2967 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 3 | 2016 | 1350 | 0.140 |
Why?
|
| Mutation | 11 | 2018 | 15179 | 0.140 |
Why?
|
| Prospective Studies | 18 | 2022 | 12873 | 0.140 |
Why?
|
| Chronobiology Phenomena | 2 | 1993 | 5 | 0.140 |
Why?
|
| Prostate-Specific Antigen | 1 | 2020 | 993 | 0.140 |
Why?
|
| Pneumonectomy | 1 | 2021 | 831 | 0.140 |
Why?
|
| Cytarabine | 4 | 2012 | 1973 | 0.140 |
Why?
|
| Drug Therapy | 3 | 1995 | 205 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2015 | 5539 | 0.140 |
Why?
|
| Breast | 5 | 2024 | 1344 | 0.140 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 980 | 0.140 |
Why?
|
| Publication Bias | 1 | 2015 | 38 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2020 | 2232 | 0.130 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 4320 | 0.130 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2015 | 32 | 0.130 |
Why?
|
| Epidemiologic Research Design | 2 | 2012 | 11 | 0.130 |
Why?
|
| Statistics as Topic | 3 | 2005 | 445 | 0.130 |
Why?
|
| Infant | 7 | 2021 | 13310 | 0.130 |
Why?
|
| Pyrrolidines | 1 | 2015 | 113 | 0.130 |
Why?
|
| Gene Expression | 4 | 2015 | 3570 | 0.130 |
Why?
|
| Observer Variation | 1 | 1996 | 671 | 0.130 |
Why?
|
| Family | 3 | 2002 | 736 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.130 |
Why?
|
| Haemophilus Vaccines | 1 | 1994 | 40 | 0.130 |
Why?
|
| Genetic Carrier Screening | 2 | 2007 | 92 | 0.130 |
Why?
|
| Prevalence | 4 | 2013 | 3260 | 0.130 |
Why?
|
| Cancer Care Facilities | 2 | 2017 | 884 | 0.130 |
Why?
|
| Heterozygote | 6 | 2006 | 1020 | 0.130 |
Why?
|
| Direct Service Costs | 1 | 2014 | 12 | 0.120 |
Why?
|
| Contrast Media | 1 | 2021 | 1472 | 0.120 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2018 | 211 | 0.120 |
Why?
|
| Pedigree | 4 | 2005 | 1890 | 0.120 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2017 | 565 | 0.120 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2015 | 110 | 0.120 |
Why?
|
| Haemophilus Infections | 1 | 1994 | 103 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2003 | 1823 | 0.120 |
Why?
|
| Safety | 2 | 2007 | 465 | 0.120 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 245 | 0.120 |
Why?
|
| Deoxycytidine | 2 | 2010 | 1353 | 0.120 |
Why?
|
| Medical Futility | 1 | 2014 | 54 | 0.120 |
Why?
|
| Methotrexate | 8 | 2019 | 999 | 0.120 |
Why?
|
| Nomograms | 2 | 2006 | 313 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2018 | 8873 | 0.120 |
Why?
|
| Quality-Adjusted Life Years | 4 | 2014 | 226 | 0.120 |
Why?
|
| Forecasting | 2 | 2013 | 694 | 0.120 |
Why?
|
| History, 21st Century | 2 | 2024 | 441 | 0.120 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 1048 | 0.110 |
Why?
|
| Arrhythmias, Cardiac | 3 | 1987 | 473 | 0.110 |
Why?
|
| Occlusive Dressings | 1 | 1992 | 14 | 0.110 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2013 | 195 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2016 | 428 | 0.110 |
Why?
|
| Polyurethanes | 1 | 1992 | 36 | 0.110 |
Why?
|
| Remission Induction | 8 | 2022 | 3569 | 0.110 |
Why?
|
| Meat | 1 | 2013 | 87 | 0.110 |
Why?
|
| Therapeutic Equipoise | 1 | 2012 | 4 | 0.110 |
Why?
|
| Logistic Models | 7 | 2010 | 3441 | 0.110 |
Why?
|
| Effect Modifier, Epidemiologic | 2 | 2007 | 21 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Infant, Newborn | 4 | 2021 | 8223 | 0.100 |
Why?
|
| Neoplasm Grading | 4 | 2018 | 1742 | 0.100 |
Why?
|
| Causality | 2 | 2014 | 178 | 0.100 |
Why?
|
| Cohort Studies | 8 | 2021 | 9244 | 0.100 |
Why?
|
| Cell Nucleus | 1 | 2017 | 1620 | 0.100 |
Why?
|
| Medical Device Recalls | 1 | 2011 | 5 | 0.100 |
Why?
|
| Informed Consent | 1 | 2015 | 419 | 0.100 |
Why?
|
| Canada | 3 | 2010 | 429 | 0.100 |
Why?
|
| Terminology as Topic | 1 | 2014 | 414 | 0.100 |
Why?
|
| Decision Making | 3 | 2009 | 1287 | 0.100 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2008 | 749 | 0.100 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 2011 | 51 | 0.100 |
Why?
|
| Likelihood Functions | 3 | 2007 | 233 | 0.100 |
Why?
|
| Quinazolines | 2 | 2015 | 923 | 0.100 |
Why?
|
| Gene Expression Profiling | 5 | 2018 | 5159 | 0.100 |
Why?
|
| Carcinoma | 2 | 2015 | 2578 | 0.100 |
Why?
|
| Risk | 6 | 2016 | 1972 | 0.100 |
Why?
|
| Adenosine Deaminase Inhibitors | 1 | 2010 | 24 | 0.100 |
Why?
|
| Fruit | 1 | 2013 | 294 | 0.100 |
Why?
|
| Cardiovascular Agents | 1 | 2012 | 128 | 0.100 |
Why?
|
| Histamine | 1 | 2011 | 53 | 0.100 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2015 | 502 | 0.100 |
Why?
|
| Pentostatin | 1 | 2010 | 119 | 0.090 |
Why?
|
| Catheterization, Peripheral | 1 | 1992 | 158 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2003 | 3518 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2018 | 2231 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2015 | 2203 | 0.090 |
Why?
|
| Child | 5 | 2021 | 29154 | 0.090 |
Why?
|
| Medulloblastoma | 1 | 2015 | 540 | 0.090 |
Why?
|
| Models, Genetic | 2 | 2020 | 1113 | 0.090 |
Why?
|
| ROC Curve | 1 | 2013 | 1183 | 0.090 |
Why?
|
| Acute Disease | 3 | 2012 | 2422 | 0.090 |
Why?
|
| Menopause | 3 | 2007 | 159 | 0.090 |
Why?
|
| Analgesics | 1 | 2013 | 390 | 0.090 |
Why?
|
| Gene Amplification | 3 | 2009 | 731 | 0.090 |
Why?
|
| Evidence-Based Medicine | 2 | 2015 | 1085 | 0.090 |
Why?
|
| Interleukin-2 | 2 | 2011 | 842 | 0.090 |
Why?
|
| Catheterization, Central Venous | 1 | 1992 | 354 | 0.090 |
Why?
|
| Transplantation, Autologous | 3 | 2011 | 1914 | 0.090 |
Why?
|
| Tissue Array Analysis | 1 | 2011 | 760 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 4 | 1998 | 1581 | 0.090 |
Why?
|
| Cognition | 1 | 2015 | 968 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2013 | 667 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2020 | 5178 | 0.080 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2009 | 116 | 0.080 |
Why?
|
| Motivation | 1 | 2012 | 499 | 0.080 |
Why?
|
| Carcinoma in Situ | 1 | 2012 | 487 | 0.080 |
Why?
|
| Interleukin-6 | 2 | 2020 | 1038 | 0.080 |
Why?
|
| Syndrome | 1 | 2012 | 1351 | 0.080 |
Why?
|
| Motor Activity | 1 | 2013 | 693 | 0.080 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2012 | 362 | 0.080 |
Why?
|
| World Health Organization | 1 | 2010 | 316 | 0.080 |
Why?
|
| Child, Preschool | 4 | 2021 | 16273 | 0.080 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2007 | 342 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1249 | 0.080 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2013 | 363 | 0.080 |
Why?
|
| Diagnostic Imaging | 2 | 2013 | 1162 | 0.080 |
Why?
|
| Leukemia | 3 | 2007 | 1635 | 0.080 |
Why?
|
| Pyridines | 1 | 2015 | 1244 | 0.080 |
Why?
|
| Receptors, Steroid | 3 | 2019 | 286 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 1303 | 0.080 |
Why?
|
| Least-Squares Analysis | 1 | 2007 | 66 | 0.080 |
Why?
|
| Patient Education as Topic | 2 | 2004 | 748 | 0.080 |
Why?
|
| Pilot Projects | 5 | 2008 | 2803 | 0.080 |
Why?
|
| Prostatic Neoplasms | 2 | 2020 | 5767 | 0.080 |
Why?
|
| Patient Safety | 1 | 2013 | 649 | 0.080 |
Why?
|
| CpG Islands | 1 | 2009 | 633 | 0.080 |
Why?
|
| Cytotoxins | 1 | 2007 | 66 | 0.080 |
Why?
|
| Critical Care | 1 | 1993 | 770 | 0.080 |
Why?
|
| Macrophages | 1 | 2013 | 1304 | 0.070 |
Why?
|
| Precancerous Conditions | 1 | 2014 | 1058 | 0.070 |
Why?
|
| Stochastic Processes | 1 | 2007 | 44 | 0.070 |
Why?
|
| Genes, p53 | 3 | 2006 | 1090 | 0.070 |
Why?
|
| Intraoperative Care | 1 | 2008 | 259 | 0.070 |
Why?
|
| Educational Status | 2 | 2006 | 397 | 0.070 |
Why?
|
| Glutamates | 1 | 2007 | 130 | 0.070 |
Why?
|
| Surveys and Questionnaires | 4 | 2017 | 5687 | 0.070 |
Why?
|
| Guanine | 1 | 2007 | 151 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2010 | 2403 | 0.070 |
Why?
|
| Double-Blind Method | 4 | 2015 | 2588 | 0.070 |
Why?
|
| Adolescent | 6 | 2021 | 31252 | 0.070 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2017 | 1415 | 0.070 |
Why?
|
| Flecainide | 5 | 1989 | 27 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1945 | 0.070 |
Why?
|
| Recurrence | 2 | 2012 | 4758 | 0.070 |
Why?
|
| Lymphoma, Follicular | 1 | 2011 | 587 | 0.070 |
Why?
|
| Cell Proliferation | 3 | 2017 | 7226 | 0.070 |
Why?
|
| Axilla | 5 | 2017 | 902 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2007 | 298 | 0.070 |
Why?
|
| Morbidity | 1 | 2007 | 397 | 0.070 |
Why?
|
| Information Services | 1 | 2006 | 50 | 0.070 |
Why?
|
| Receptor, TIE-2 | 2 | 2024 | 82 | 0.070 |
Why?
|
| Analysis of Variance | 3 | 2004 | 2307 | 0.070 |
Why?
|
| Penetrance | 1 | 2006 | 126 | 0.070 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 672 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2012 | 1209 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 586 | 0.070 |
Why?
|
| Cancer Vaccines | 1 | 2011 | 697 | 0.070 |
Why?
|
| Breast Neoplasms, Male | 2 | 2008 | 229 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2010 | 492 | 0.060 |
Why?
|
| Focus Groups | 2 | 2016 | 256 | 0.060 |
Why?
|
| Diet | 1 | 2013 | 1440 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 7702 | 0.060 |
Why?
|
| Bone Neoplasms | 2 | 2010 | 2576 | 0.060 |
Why?
|
| BRCA2 Protein | 3 | 2002 | 358 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2007 | 2218 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 4 | 2021 | 4367 | 0.060 |
Why?
|
| Emergency Service, Hospital | 1 | 2012 | 1148 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 4 | 2009 | 3203 | 0.060 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 1946 | 0.060 |
Why?
|
| Vaccines, Combined | 1 | 2004 | 39 | 0.060 |
Why?
|
| Chickenpox Vaccine | 1 | 2004 | 18 | 0.060 |
Why?
|
| Chromosomes, Human | 1 | 2005 | 295 | 0.060 |
Why?
|
| Neoplasm Proteins | 3 | 2004 | 3230 | 0.060 |
Why?
|
| Genetics, Population | 1 | 2005 | 242 | 0.060 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2004 | 16 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 1375 | 0.060 |
Why?
|
| Catheter Ablation | 1 | 2010 | 620 | 0.060 |
Why?
|
| Drug Interactions | 5 | 2013 | 553 | 0.060 |
Why?
|
| Genetic Linkage | 1 | 2005 | 512 | 0.060 |
Why?
|
| Glioma | 1 | 2015 | 1963 | 0.060 |
Why?
|
| Pravastatin | 1 | 2004 | 34 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 4654 | 0.060 |
Why?
|
| Inbreeding | 1 | 2003 | 11 | 0.060 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 2265 | 0.060 |
Why?
|
| Manuals as Topic | 1 | 2003 | 17 | 0.060 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2005 | 135 | 0.060 |
Why?
|
| Rosuvastatin Calcium | 1 | 2003 | 43 | 0.060 |
Why?
|
| Azacitidine | 1 | 2010 | 1149 | 0.060 |
Why?
|
| Dioxolanes | 1 | 2003 | 41 | 0.060 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 2315 | 0.060 |
Why?
|
| Melanoma | 1 | 2020 | 5317 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2007 | 649 | 0.060 |
Why?
|
| Cadherins | 1 | 2006 | 660 | 0.060 |
Why?
|
| Transplantation Conditioning | 2 | 2010 | 2238 | 0.060 |
Why?
|
| Retrospective Studies | 11 | 2021 | 37905 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2006 | 507 | 0.060 |
Why?
|
| Algorithms | 3 | 2015 | 3890 | 0.050 |
Why?
|
| Insulin, Regular, Human | 1 | 2022 | 12 | 0.050 |
Why?
|
| Prostheses and Implants | 1 | 2005 | 295 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2009 | 1506 | 0.050 |
Why?
|
| Cytosine | 1 | 2003 | 141 | 0.050 |
Why?
|
| Atrial Fibrillation | 1 | 2010 | 719 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2003 | 203 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 14551 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2006 | 803 | 0.050 |
Why?
|
| Cisplatin | 5 | 2009 | 2432 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 2 | 2000 | 1547 | 0.050 |
Why?
|
| Hematoma, Subdural | 1 | 2021 | 28 | 0.050 |
Why?
|
| Maytansine | 1 | 2021 | 38 | 0.050 |
Why?
|
| Skin | 1 | 1987 | 1259 | 0.050 |
Why?
|
| Viral Vaccines | 1 | 2004 | 304 | 0.050 |
Why?
|
| Propranolol | 3 | 1987 | 156 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2024 | 574 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 5437 | 0.050 |
Why?
|
| Equipment Design | 1 | 2005 | 1204 | 0.050 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2021 | 151 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 1054 | 0.050 |
Why?
|
| Obesity | 1 | 2014 | 2884 | 0.050 |
Why?
|
| Phylogeny | 1 | 2003 | 826 | 0.050 |
Why?
|
| Pelvic Neoplasms | 1 | 2002 | 189 | 0.050 |
Why?
|
| Transcriptome | 2 | 2020 | 1859 | 0.050 |
Why?
|
| Aging | 1 | 2009 | 1582 | 0.050 |
Why?
|
| Area Under Curve | 2 | 2018 | 700 | 0.050 |
Why?
|
| Aspirin | 1 | 2004 | 455 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2004 | 444 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2020 | 181 | 0.050 |
Why?
|
| Azithromycin | 1 | 2020 | 78 | 0.050 |
Why?
|
| Treatment Failure | 3 | 2010 | 1391 | 0.050 |
Why?
|
| Imides | 2 | 1999 | 10 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2000 | 68 | 0.040 |
Why?
|
| Graft vs Host Disease | 1 | 2010 | 2638 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2022 | 403 | 0.040 |
Why?
|
| Cause of Death | 3 | 2005 | 752 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 3 | 2015 | 3981 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2009 | 2669 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2007 | 4314 | 0.040 |
Why?
|
| Epirubicin | 2 | 2013 | 157 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2002 | 493 | 0.040 |
Why?
|
| Phthalazines | 1 | 2021 | 253 | 0.040 |
Why?
|
| Alleles | 1 | 2005 | 2437 | 0.040 |
Why?
|
| Megestrol Acetate | 1 | 1999 | 29 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2004 | 509 | 0.040 |
Why?
|
| Isoquinolines | 2 | 1999 | 116 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 7551 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2012 | 3869 | 0.040 |
Why?
|
| Radiation Tolerance | 2 | 2017 | 629 | 0.040 |
Why?
|
| Cell Movement | 1 | 2006 | 2466 | 0.040 |
Why?
|
| SELEX Aptamer Technique | 1 | 2018 | 5 | 0.040 |
Why?
|
| Aminoglycosides | 1 | 1999 | 220 | 0.040 |
Why?
|
| Comorbidity | 2 | 2016 | 2352 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2014 | 756 | 0.040 |
Why?
|
| Leukemia, Myeloid | 1 | 2003 | 941 | 0.040 |
Why?
|
| Machine Learning | 1 | 2020 | 319 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 146 | 0.040 |
Why?
|
| Ondansetron | 1 | 1998 | 42 | 0.040 |
Why?
|
| Osteosarcoma | 1 | 2005 | 929 | 0.040 |
Why?
|
| DNA, Single-Stranded | 1 | 2018 | 106 | 0.040 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2001 | 588 | 0.040 |
Why?
|
| Ovariectomy | 1 | 1998 | 330 | 0.040 |
Why?
|
| Body Weight | 1 | 2002 | 1293 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2002 | 1459 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2017 | 254 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2003 | 1335 | 0.040 |
Why?
|
| Visual Analog Scale | 1 | 2016 | 13 | 0.040 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 1998 | 122 | 0.040 |
Why?
|
| Antiemetics | 1 | 1998 | 125 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2017 | 6150 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2018 | 213 | 0.030 |
Why?
|
| Culture | 1 | 2016 | 100 | 0.030 |
Why?
|
| Insulin | 1 | 2022 | 1454 | 0.030 |
Why?
|
| Thiotepa | 1 | 1996 | 118 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2009 | 4821 | 0.030 |
Why?
|
| Genomics | 2 | 2018 | 2738 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 1997 | 359 | 0.030 |
Why?
|
| Filgrastim | 2 | 2008 | 191 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2020 | 717 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2012 | 4557 | 0.030 |
Why?
|
| Netherlands | 1 | 2015 | 83 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 2012 | 1382 | 0.030 |
Why?
|
| Italy | 1 | 2005 | 236 | 0.030 |
Why?
|
| Electrocardiography | 4 | 1990 | 1145 | 0.030 |
Why?
|
| Toremifene | 1 | 1995 | 8 | 0.030 |
Why?
|
| Ligands | 1 | 2018 | 995 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2003 | 849 | 0.030 |
Why?
|
| Recombinant Proteins | 3 | 2008 | 2927 | 0.030 |
Why?
|
| Carmustine | 3 | 2002 | 214 | 0.030 |
Why?
|
| Phenotype | 2 | 2018 | 6295 | 0.030 |
Why?
|
| Neutropenia | 2 | 2014 | 968 | 0.030 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2000 | 674 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 313 | 0.030 |
Why?
|
| Ethics, Research | 1 | 2015 | 67 | 0.030 |
Why?
|
| Gene Editing | 1 | 2017 | 216 | 0.030 |
Why?
|
| Southwestern United States | 1 | 1994 | 62 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2017 | 424 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2014 | 945 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2017 | 556 | 0.030 |
Why?
|
| Indians, North American | 1 | 1994 | 87 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 1994 | 425 | 0.030 |
Why?
|
| Cardiovascular Diseases | 2 | 2004 | 2195 | 0.030 |
Why?
|
| Critical Pathways | 1 | 2015 | 149 | 0.030 |
Why?
|
| Heart Ventricles | 4 | 1990 | 846 | 0.030 |
Why?
|
| Haemophilus influenzae | 1 | 1994 | 144 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 323 | 0.030 |
Why?
|
| Transcription Factors | 2 | 1998 | 5270 | 0.030 |
Why?
|
| Logic | 1 | 1993 | 10 | 0.030 |
Why?
|
| Hemodynamics | 2 | 1989 | 935 | 0.030 |
Why?
|
| Program Development | 1 | 2015 | 261 | 0.030 |
Why?
|
| Philosophy, Medical | 1 | 1993 | 24 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1998 | 661 | 0.030 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1994 | 133 | 0.030 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1993 | 123 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 1998 | 891 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2013 | 67 | 0.030 |
Why?
|
| Survival | 2 | 2003 | 177 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 1998 | 3033 | 0.030 |
Why?
|
| ErbB Receptors | 2 | 2008 | 2295 | 0.030 |
Why?
|
| Administration, Oral | 3 | 2010 | 1544 | 0.030 |
Why?
|
| Registries | 2 | 2005 | 2170 | 0.030 |
Why?
|
| Esophagectomy | 1 | 2017 | 911 | 0.030 |
Why?
|
| Piperazines | 1 | 2021 | 2101 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 1290 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2016 | 479 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2012 | 182 | 0.030 |
Why?
|
| Computational Biology | 1 | 2018 | 1271 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 1021 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 2291 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 1516 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 2054 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 1993 | 330 | 0.020 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 338 | 0.020 |
Why?
|
| Cardiac Complexes, Premature | 1 | 1990 | 5 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2015 | 701 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 666 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2014 | 627 | 0.020 |
Why?
|
| Research | 1 | 1993 | 415 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2010 | 130 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 227 | 0.020 |
Why?
|
| Micro-Electrical-Mechanical Systems | 1 | 2010 | 5 | 0.020 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2010 | 12 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2012 | 486 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 2483 | 0.020 |
Why?
|
| Communication | 1 | 2017 | 876 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 280 | 0.020 |
Why?
|
| Piperidines | 2 | 1986 | 1035 | 0.020 |
Why?
|
| Ethics, Medical | 1 | 1993 | 442 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2011 | 144 | 0.020 |
Why?
|
| Endometrial Neoplasms | 1 | 1999 | 1341 | 0.020 |
Why?
|
| Verapamil | 1 | 1989 | 78 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1997 | 2358 | 0.020 |
Why?
|
| Tacrolimus | 1 | 2010 | 335 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2011 | 299 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 846 | 0.020 |
Why?
|
| Karyotyping | 2 | 2003 | 1022 | 0.020 |
Why?
|
| Biopsy | 1 | 2017 | 3443 | 0.020 |
Why?
|
| Survivors | 1 | 2014 | 1031 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 1992 | 479 | 0.020 |
Why?
|
| Genotype | 2 | 2007 | 4109 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2008 | 105 | 0.020 |
Why?
|
| Fatigue | 1 | 2014 | 1239 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 1998 | 6100 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2010 | 333 | 0.020 |
Why?
|
| Naphthalimides | 2 | 1999 | 14 | 0.020 |
Why?
|
| Cardiac Output | 2 | 1986 | 194 | 0.020 |
Why?
|
| Drug Industry | 1 | 1988 | 88 | 0.020 |
Why?
|
| Patient Advocacy | 1 | 2008 | 92 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2012 | 1014 | 0.020 |
Why?
|
| Vascular Resistance | 2 | 1986 | 200 | 0.020 |
Why?
|
| Ethics, Clinical | 1 | 2008 | 78 | 0.020 |
Why?
|
| Hair | 1 | 1987 | 42 | 0.020 |
Why?
|
| Digoxin | 1 | 1987 | 63 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2007 | 102 | 0.020 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 1993 | 581 | 0.020 |
Why?
|
| Organophosphonates | 2 | 1999 | 64 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 1085 | 0.020 |
Why?
|
| Labetalol | 1 | 1986 | 12 | 0.020 |
Why?
|
| Atenolol | 1 | 1986 | 42 | 0.020 |
Why?
|
| Hypertension | 2 | 2014 | 1503 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2012 | 899 | 0.020 |
Why?
|
| Jews | 1 | 2006 | 59 | 0.020 |
Why?
|
| Endosomes | 1 | 2006 | 109 | 0.020 |
Why?
|
| France | 1 | 2005 | 108 | 0.020 |
Why?
|
| Endocytosis | 1 | 2006 | 225 | 0.020 |
Why?
|
| Norway | 1 | 2005 | 30 | 0.020 |
Why?
|
| Osteitis | 1 | 2005 | 17 | 0.020 |
Why?
|
| Age of Onset | 1 | 2007 | 827 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2010 | 1244 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2011 | 1987 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 1360 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 1323 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2008 | 829 | 0.020 |
Why?
|
| Lymphoma, B-Cell | 1 | 2012 | 895 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1994 | 2488 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 2864 | 0.020 |
Why?
|
| Hyperparathyroidism | 1 | 2005 | 93 | 0.020 |
Why?
|
| Mastectomy, Radical | 1 | 2004 | 39 | 0.020 |
Why?
|
| Cardiovascular System | 1 | 1986 | 145 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2006 | 344 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 1764 | 0.020 |
Why?
|
| Protein Transport | 1 | 2006 | 734 | 0.020 |
Why?
|
| S Phase | 2 | 1995 | 281 | 0.020 |
Why?
|
| Adenine | 2 | 1999 | 631 | 0.020 |
Why?
|
| Vincristine | 2 | 2003 | 1511 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2004 | 334 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 4757 | 0.010 |
Why?
|
| Quality of Life | 2 | 2010 | 4532 | 0.010 |
Why?
|
| Viscera | 1 | 2003 | 81 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2006 | 1643 | 0.010 |
Why?
|
| Heart Diseases | 1 | 1989 | 732 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2006 | 1163 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 7222 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 1399 | 0.010 |
Why?
|
| Leucovorin | 1 | 2003 | 332 | 0.010 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2012 | 1763 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 3639 | 0.010 |
Why?
|
| North Carolina | 1 | 2002 | 125 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2008 | 1529 | 0.010 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2002 | 153 | 0.010 |
Why?
|
| Idarubicin | 1 | 2003 | 446 | 0.010 |
Why?
|
| Animals | 2 | 2015 | 59536 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 1248 | 0.010 |
Why?
|
| Prednisone | 1 | 2003 | 984 | 0.010 |
Why?
|
| Health Surveys | 1 | 2002 | 402 | 0.010 |
Why?
|
| Smoking | 1 | 1989 | 2440 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2008 | 4804 | 0.010 |
Why?
|
| Protein Binding | 1 | 2006 | 3438 | 0.010 |
Why?
|
| Health Status | 1 | 2003 | 590 | 0.010 |
Why?
|
| Trimetrexate | 1 | 1999 | 12 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2001 | 593 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2004 | 889 | 0.010 |
Why?
|
| Fever | 1 | 2002 | 497 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 5395 | 0.010 |
Why?
|
| Life Expectancy | 1 | 1999 | 129 | 0.010 |
Why?
|
| Estrogen Antagonists | 1 | 1999 | 184 | 0.010 |
Why?
|
| Research Subjects | 1 | 1999 | 65 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 2 | 1989 | 231 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2002 | 1046 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2004 | 1824 | 0.010 |
Why?
|
| Melphalan | 1 | 1999 | 834 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1999 | 974 | 0.010 |
Why?
|
| Hysterectomy | 1 | 1999 | 611 | 0.010 |
Why?
|
| Ploidies | 1 | 1995 | 248 | 0.010 |
Why?
|
| Breast Diseases | 1 | 1997 | 201 | 0.010 |
Why?
|
| Apoptosis | 1 | 2008 | 7591 | 0.010 |
Why?
|
| Heart Rate | 2 | 1987 | 737 | 0.010 |
Why?
|
| Kinetics | 1 | 1995 | 2049 | 0.010 |
Why?
|
| Blood Pressure | 2 | 1990 | 1467 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 1998 | 1960 | 0.010 |
Why?
|
| Information Systems | 1 | 1990 | 54 | 0.010 |
Why?
|
| Software Design | 1 | 1990 | 40 | 0.010 |
Why?
|
| Periodicity | 1 | 1990 | 68 | 0.010 |
Why?
|
| Work Schedule Tolerance | 1 | 1990 | 53 | 0.010 |
Why?
|
| Cell Cycle | 1 | 1995 | 2084 | 0.010 |
Why?
|
| Tachycardia, Supraventricular | 1 | 1990 | 84 | 0.010 |
Why?
|
| Prednisolone | 1 | 1989 | 123 | 0.010 |
Why?
|
| Mercaptopurine | 1 | 1989 | 130 | 0.010 |
Why?
|
| Asparaginase | 1 | 1989 | 184 | 0.000 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1989 | 209 | 0.000 |
Why?
|
| Hydrocortisone | 1 | 1989 | 388 | 0.000 |
Why?
|
| Reference Values | 1 | 1989 | 1099 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1999 | 2992 | 0.000 |
Why?
|
| Echocardiography | 1 | 1989 | 1182 | 0.000 |
Why?
|
| Drug Synergism | 1 | 1987 | 1313 | 0.000 |
Why?
|